Skip to main content
SpringerLink
Log in

PML reported with efalizumab

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Genentech Inc.Important safety information. Internet Document: [2 pages], Oct 2008. Available from: URL: http://www.gene.com

  2. Merck KGaA, Merck Serono.Severe Adverse Event Reported in Raptiva (Rm) Patient. Media Release: 3 Oct 2008. Available from: URL: http://www.merck.de

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

PML reported with efalizumab. React. Wkly. 1223, 2 (2008). https://doi.org/10.2165/00128415-200812230-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200812230-00005

Keywords

Search

Navigation